Nancy Dahms, PhD, Appointed to Scientific Advisory Board of Biotech Company M6P Therapeutics
The Missouri-based biotechnology company M6P Therapeutics, which develops enzyme and gene therapies for lysosomal storage disorders, has appointed Dr. Nancy Dahms, Professor of Biochemistry at the Medical College of Wisconsin, to their scientific advisory board. The company is named for the sugar mannose-6-phosphate, which acts as a signal flag to promote trafficking of enzymes destined for the lysosome. Without the sugar, enzymes don't make it to the lysosome — and absence of certain enzymes can cause lysosomal buildup of their substrates. Lysosomal storage disorders are generally rare diseases but can be very serious. The company is developing a gene therapeutic approach that expresses both a missing lysosomal enzyme and a phosphotransferase that enables proper lysosomal targeting. Dr. Dahms studies mannose-6-phosphate receptors that govern lysosomal enzyme targeting and Fabry disease, a lysosomal storage disorder caused by buildup of a glycosphingolipid when a certain lysosomal glycan-digesting enzyme is mutated or absent. Dr. Dahms is the 2021 president of the Society for Glycobiology.